Potassium canrenoate
Pharmaceutical drug
- C03DA02 (WHO)
- potassium 3-[(8R,9S,10R,13S,14S,17R)-
17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,
11,12,14,15,16-octahydro-1H-cyclopenta[a]
phenanthren-17-yl]propanoate
- 2181-04-6
N
- 23671691
- DB09015 N
- 570975
Y
- M671F9NLEA
- ChEMBL1371200 N
- DTXSID2045602
- Interactive image
- [K+].[O-]C(=O)CC[C@]3(O)CC[C@H]2[C@@H]4/C=C\C1=C\C(=O)CC[C@@]1([C@H]4CC[C@@]23C)C
InChI
- InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1Y
- Key:JTZQCHFUGHIPDF-RYVBEKKQSA-MY
N
Y (what is this?) (verify)Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium,[1] the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.[2] Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.[3][4]
Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous)[4][5] as opposed to oral administration.[6]
In the UK, it is unlicensed and only used for short term diuresis in oedema or heart failure in neonates or children under specialist initiation and monitoring.
See also
References
- ^ Selye H (17 April 2013). Hormones and Resistance: Part 1 and. Springer Science & Business Media. pp. 186–. ISBN 978-3-642-65192-2.
- ^ Hill RA, Makin HL, Kirk DN, Murphy GM (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
- ^ Burger A, Wolff ME (1996). Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents. Wiley. ISBN 978-0-471-57557-3.
- ^ a b Waldmann C, Soni N, Rhodes A (27 November 2008). "Diurectics and the Critical Ill". Oxford Desk Reference: Critical Care. OUP Oxford. pp. 187–. ISBN 978-0-19-922958-1.
- ^ Santambrogio R, Barabino M, Opocher E (21 June 2017). "Non-resection: Radiofrequency Ablation, Cryo, Microwave". In Bonjer HJ (ed.). Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES). Springer. pp. 136–. ISBN 978-3-319-43196-3.
- ^ Kolkhof P, Bärfacker L (July 2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". The Journal of Endocrinology. 234 (1): T125–T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.
- v
- t
- e
(and etacrynic acid)
| CA inhibitors (at PT) | |
|---|---|
| Loop (Na-K-Cl at AL) | |
| Thiazides (Na-Cl at DCT, Calcium-sparing) | |
| Thiazide-likes (primarily DCT) |
| ESC blockers | |
|---|---|
| Aldosterone antagonists |
|
(DCT and CD)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
